(2R)-2-[(甲基氨基)甲基]-1-吡咯烷羧酸叔丁酯 | 783325-25-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: (2R)-2-[(甲基氨基)甲基]-1-吡咯烷羧酸叔丁酯
• 中文别名: (R)-1-boc-2-(甲基氨基甲基)-吡咯烷
• 英文名称: (R)-2-methylaminomethyl-1-BOC-pyrrolidine
• 英文别名: (R)-tert-butyl 2-((methylamino)methyl)pyrrolidine-1-carboxylate；tert-butyl (2R)-2-(methylaminomethyl)pyrrolidine-1-carboxylate
• CAS: 783325-25-7
• 化学式: C₁₁H₂₂N₂O₂
• 分子量: 214.308
• InChiKey: NHOPGDPSLMBDQD-SECBINFHSA-N

物化性质

• 沸点：
  282℃
• 密度：
  1.004
• 闪点：
  124℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 储存条件：
  应存放在2-8°C的环境中，避免光照，并保持在惰性气体中。

反应信息

• 作为反应物：
  描述：

  (2R)-2-[(甲基氨基)甲基]-1-吡咯烷羧酸叔丁酯 在 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 24.0h， 生成 2-(furan-2-yl)-5-N-methyl-5-N-[[(2R)-1-[(5-methyl-1,2-oxazol-3-yl)methyl]pyrrolidin-2-yl]methyl]-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine
  参考文献：
  名称：

  Novel Diamino Derivatives of [1,2,4]Triazolo[1,5-a][1,3,5]triazine as Potent and Selective Adenosine A_2a Receptor Antagonists

  摘要：

  Piperazine derivatives of 2-furanyl[1,2,4]triazolo[1,5-a][1,3,5]triazine have recently been demonstrated to be potent and selective adenosine A(2a) receptor antagonists with oral activity in rodent models of Parkinson's disease. We have replaced the piperazinyl group with a variety of linear, monocyclic, and bicyclic diamines. Of these diamines, (R)-2-(aminomethyl)pyrrolidine is a particularly potent and selective replacement for the piperazinyl group. With this diamine component, we have been able to prepare numerous analogues with low nanomolar affinity toward the A(2a) receptor and good selectivity with respect to the A(1) receptor (> 200-fold in some cases). Selected analogues from this series of [1,2,4]triazolo[1,5-a][1,3,5]triazine have now been shown to be orally active in the mouse catalepsy model.

  DOI：

  10.1021/jm0498396
• 作为产物：
  描述：

  (R)-2-Methylcarbamoyl-pyrrolidine-1-carboxylic acid tert-butyl ester 在 硼烷四氢呋喃络合物 、 甲醇 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 (2R)-2-[(甲基氨基)甲基]-1-吡咯烷羧酸叔丁酯
  参考文献：
  名称：

  [EN] TRIAZOLO[1,5-C]PYRIMIDINES AND PYRAZOLO[1,5-C]PYRIMIDINES USEFUL AS A2A ADENOSIN E RECEPTOR ANTAGONISTS
  [FR] TRIAZOLO[1,5-C]PYRIMIDINES ET PYRAZOLO[1,5-C]PYRIMIDINES ET PROCEDES DE PREPARATION ET D'UTILISATION DE CELLES-CI

  摘要：

  公开号：

  WO2004092172A3

文献信息

• [EN] HETEROARYL COMPOUNDS FOR KINASE INHIBITION<br/>[FR] COMPOSÉS HÉTÉROARYLE D'INHIBITION DE LA KINASE
  申请人：ARIAD PHARMA INC

  公开号：WO2015195228A1

  公开（公告）日：2015-12-23

  Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.

  调节激酶活性的化合物和药物组合物，包括突变的EGFR和突变的HER2激酶活性，以及与激酶活性相关的疾病和病况的治疗方法、化合物、药物组合物，包括突变的EGFR和突变的HER2活性，均在本文中描述。
• Triazolo&lsqb; 1,5-A&rsqb; Pyrimidines And Pyrazolo&lsqb; 1,5-A&rsqb; Pyrimidines And Methods Of Making And Using The Same
  申请人：Vu Chi

  公开号：US20080070932A1

  公开（公告）日：2008-03-20

  The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagofiists. thereof for preventing and/or treating numerous diseases, including C) Parkinson's disease. In one embodiment, the invention features a compound of formual (I).

  该发明基于发现，式（I）化合物具有意外的高亲和力，可用作A2a腺苷受体的拮抗剂，可用于预防和/或治疗包括帕金森病在内的许多疾病。在一种实施例中，该发明涉及式（I）化合物。
• Triazolotriazines and pyrazolotriazines and methods of making and using the same
  申请人：Vu Chi

  公开号：US20060276475A1

  公开（公告）日：2006-12-07

  The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A 2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula I: (I)

  该发明基于发现，化合物(I)的公式具有意外的高亲和力，可用作拮抗剂，用于预防和/或治疗许多疾病，包括帕金森病的A2a腺苷受体。在一种实施例中，该发明涉及公式I的化合物：(I)。
• Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
  申请人：Vu Chi

  公开号：US20070010522A1

  公开（公告）日：2007-01-11

  The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).

  该发明基于发现，公式（I）化合物具有意外高的亲和力，可以作为A2a腺苷受体的拮抗剂，用于预防和/或治疗许多疾病，包括帕金森病。在一种实施例中，该发明涉及公式（I）的化合物。
• PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES
  申请人：ARIAD Pharmaceuticals, Inc.

  公开号：EP3778584A1

  公开（公告）日：2021-02-17

  Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFRand mutant HER2 activity, are described herein.

  本文描述了调节激酶活性（包括突变型表皮生长因子受体和突变型 HER2 激酶活性）的化合物和药物组合物，以及治疗与激酶活性（包括突变型表皮生长因子受体和突变型 HER2 活性）相关的疾病和病症的化合物、药物组合物和方法。